Bone tissue engineering - a field for new medicinal products?

Area of Science:

• Biotechnology
• Regenerative Medicine
• Biomaterials

Background:

• European Union regulation in 2008 classified Tissue Engineered Products (TEPs) as Advanced Therapy Medicinal Products.
• Tissue Engineering (TE) experienced initial enthusiasm followed by a period of disappointment.
• Despite growing scientific interest, TEPs have modest market representation.

Purpose of the Study:

• To review the concept, experimental evaluation, and clinical potency of Tissue Engineering (TE).
• To focus specifically on bone tissue engineered products (BTEPs).
• To discuss the transition from laboratory research to clinical application and future prospects.

Main Methods:

• Literature review of Tissue Engineering (TE) concepts and applications.
• Analysis of experimental data and clinical potency of TEPs.
• Discussion of regulatory frameworks and market integration.

Main Results:

• TEPs are recognized within pharmaceutical biotechnology under EU regulations.
• A critical evaluation of the bench-to-clinic pathway, including animal study data, is presented.
• Bone tissue engineered products (BTEPs) show promising potential for future clinical use.

Conclusions:

• The regulatory landscape for TEPs has evolved, impacting their classification and potential.
• Challenges remain in translating TE research into widespread clinical practice.
• Bone tissue engineering holds significant promise for future therapeutic applications.